The tested intravaginal rings were capable of delivering effective doses of several anti-retroviral agents, including betulinol, and may provide a synergistic effect in the inhibition of HIV infections.
“Development of vaginal rings. . .” 2007An in vitro study of the active ingredients in BioRings’ intra vaginal ring device demonstrated that the ring delivery mechanism supplied an effective dose of the contraceptive formulation, preventing the survival of human sperm for up to 28 days. The ring also delivered effective doses of AZT, an anti-HIV agent, for 28 days.
“Efficacy of nonhormonal vaginal . . .” 2004A hydrogel-based intravaginal ring device is an effective delivery mechanism for both non-hormonal contraceptives and, potentially, anti-SID, anti-HIV, and pelvic disease agents.
“Intravaginal Rings (IVR) to deliver. . .”Results of an in vitro study suggest that an intravaginal ring is capable of releasing daily efficacious amounts of microbicides and non-hormonal contraceptives at concentrations higher than the minimal effective dose.
“New study finds little progress in meeting demand. . .”A new study by the Guttmacher Institute and UNFPA, the United Nations Population Fund, finds that the number of women in developing countries who want to avoid pregnancy but are not using modern contraception declined only slightly between 2008 and 2012, from 226 to 222 million.
Presentation: “The Value of BioRings” [pdf]
Poster: “Intra-vaginal Ring (IVR) as drug delivery system: A Multiple Preventative Technology for protection against unintended pregnancy and/or HIV infection.” [pdf] Abstract: “Intra-vaginal ring (IVR) as drug delivery system, BioRings: A Multiple Preventative Technology for protection against unintended pregnancy and/or HIV infection” [pdf] * Titles for the articles above have been shortened for the Abstract.